Gernot Stuhler
MD, PhD
Professor of Hematology and Cell Therapy
👥Biography 个人简介
Dr. Gernot Stuhler is a hematologist and immunotherapy specialist who has contributed to the development and clinical evaluation of tebentafusp (IMCgp100), the first TCR bispecific T-cell engager to receive FDA approval for unresectable or metastatic uveal melanoma. He has investigated the unique biology of HLA-A*02:01-restricted T-cell engagement and the distinct mechanisms of action of TCR bispecifics compared to antibody-based engagers.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Gernot Stuhler 的研究动态
Follow Gernot Stuhler's research updates
留下邮箱，当我们发布与 Gernot Stuhler（Deutsche Klinik fur Diagnostik）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment